Unclassified · Medical Literature

[Articles] High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial

Authors
Gerald Illerhaus, Andrés J M Ferreri, Julia Wendler, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer, Alexander Röth, Gerlinde Egerer, Thomas Ernst, Thomas Weber, Bernd Hertenstein, Georg Lenz, Martin Dreyling, Robert Möhle, Guido Kobbe, Christian A Schmidt, Uta Brunnberg, Jens Panse, Michael Kneba, Thomas Heinicke, Sebastian Schroll, Thomas S Larsen, Lorenz Thurner, Tobias Pukrop, Hans Salwender, Ralph Naumann, Georg Hess, Frank P Kroschinsky, Anne K Blystad, Ulrich Keller, Elisa J Pulczynski, Martin Bjerregård Pedersen, Francesca Re, Lorella Orsucci, Lisa Pospiech, Paul La Rosée, Martina Deckert, Maurilio Ponzoni, Dennis Gmehlin, Matthias Backenstrass, Antje Jensch, Elke Valk, Teresa Calimeri, Benjamin Kasenda, Martin Trepel, Heidi Fricker, Inna Semenova, Florian Scherer, Philipp von Gottberg, Elvira Burger, Olga Grishina, Claudia Hader, Gabriele Ihorst, Jürgen Finke, Emanuele Zucca, Elisabeth Schorb
Journal
The Lancet
Publication date
2026-07-22
Source
rss_lancet
Original record ID
210173
Summary status
error
Analysis status
error
Original last updated
2026-08-10T06:56:04.000Z

Open original source

Abstract

In the largest randomised trial in untreated PCNSL to date, HCT–ASCT significantly improved progression-free and overall survival compared with non-myeloablative consolidation in patients who had completed induction treatment, establishing it as the preferred consolidation strategy in fit patients.